Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7857018 | 0.97 | GSK3A (0.51) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL31355479 | 0.87 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL31355480 | 0.87 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL3948701 | 0.87 | KMT2A (0.57) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL14843891 | 0.85 | MKNK1 (0.49) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL618208 | 0.85 | GSK3A (0.47) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL28038987 | 0.83 | HSP90AA1 (0.54) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL1323687 | 0.82 | MAPT (0.53) | CLK4KDRMKNK1CDK2CHRNB2 | |
| SCHEMBL2151545 | 0.82 | GSK3A (0.42) | GSK3ACDK9CDK5TAOK1CLK4 | |
| SCHEMBL29532960 | 0.82 | GSK3A (0.49) | GSK3ACDK9CDK5TAOK1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976336-A1 | 3-HETEROARYL SUBSTITUTED INDAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | claimed |
| CN-105209455-A | 3-heteroaryl substituted indazoles | Bayer Pharma AG | 2015-12-30 | — | — | CN | claimed |
| WO-2014147203-A1 | 3-HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20160281058-A1 | AGENTS AND METHODS FOR INHIBITING HUMAN PLURIPOTENT STEM CELL GROWTH | VIACYTE, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-2976336-A1 | 3-HETEROARYL SUBSTITUTED INDAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105209455-A | 3-heteroaryl substituted indazoles | Bayer Pharma AG | 2015-12-30 | — | — | CN | disclosed |
| US-20150329822-A1 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | Biocant - Associação De Transferência De Tecnologia (PT) | 2015-11-19 | — | — | US | disclosed |
| EP-2935567-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - Centro de Neurociências E Biologia Molecular - Universidade de Coimbra (PT) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014147203-A1 | 3-HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014097192-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA MOLECULAR - UNIVERSIDADE DE COIMBRA (PT) | 2014-06-26 | — | — | WO | disclosed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | GSK3A 1013/4885CDK9 44/4885CDK5 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.